Skip to main content

 

Patterns of Biologic Use During Autoimmune Pregnancy

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.

29 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.

22 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com.

Rituximab Efficacy in IgG4 Related Disease

PLOS reports  greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD). 

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, Vaccination and  the repeated wonders of Vitamin D.

Shingles Vaccine Studies in A&R

The current issue of Arthritis & Rheumatology features an editorial and two novel articles on the herpes zoster vaccine.

The RheumNow Week in Review – 18 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com.

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com. 

The RheumNow Week in Review – 28 July 2017

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

Forced, Rational or Glitch-Ridden Prescribing Practices

A recent analysis of 3 groups of treatment-naïve, early rheumatoid arthritis (ERA) patients looked at the factors that influenced the choice of therapy.

EULAR 2017 – Day 3 Highlights

Friday was a mega-day in Madrid as this day all the late-breaking (LB) abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.

Here are the major presentations from several clinical areas:

Lupus

Social

Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Dr. John Cush @RheumNow ( View Tweet )

5 years 5 months ago
Here's the data for GCA (even though labelled PMR) using the same methods, both looking at first 1y. Here's what gets me - it's obviously worse, but not that much worse... everyone's looking for steroid-sparing agents in GCA, but PMR's left behind? OP0275 #EULAR2020 @RheumNow https://t.co/YWkNBVitGa
David Liew @drdavidliew ( View Tweet )
5 years 6 months ago
Behcet's ulcers can be a real pain. I've heard pentoxifylline gel be discussed before, here's some early data to back it up (need bigger trial). Tastes terrible, though - so maybe this? https://t.co/TrSlIKdWX3 (or a commercial prep might solve it) SAT0260 #EULAR2020 @RheumNow https://t.co/lvDY39ZbIH
David Liew @drdavidliew ( View Tweet )
5 years 6 months ago
Whom with GCA should receive tocilizumab? What happens when it is stopped? Optimal dose for maintenance weekly or Q2 weekly? GiACTA gives only some answers. Need RWE #EULAR2020 @eular_org @RheumNow @CRASCRRheum @earlyarthritis #vasculitis https://t.co/aNvR14vfEV
5 years 6 months ago
Hand OA Rx strikes out. HCQ Rx neg and colchicine Trial negative. I wouldn’t put hand OA as same category of no Rx as for SSc and Sjogrens but agree though nuts to crack @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/QRe3UpKpbz
5 years 6 months ago
#EULAR2020 OP0333: Could SLE itself be a risk factor for retinopathy (not just because of HCQ)? @Janetbirdope study of >600 pts noted retinopathy risk factors: 1. longer duration of antimalarials 2. any use of chloroquine 3. SLE (OR 16.1 CI 2.1-125) @RheumNow https://t.co/seAR42K1SU
5 years 6 months ago
#EULAR2020 Dr. V Ritschl:EULAR Task Force on Patient Adherance: 30-80% of pts do not adhere to Rx. resulting in ⬆️dz severity, pain, fatigue, depression, decreased in function, physical activity. HCPs should discuss adherance reg. & explore factors affecting adherance. @RheumNow
5 years 6 months ago
ENbrel works in long term for the few people left on the drug at 10 yrs with SpA. Enormous dropout. If you are still on Rx for a decade you are in the minority. Drop out of TNFi in SpA mirrors RA & PsA @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/dLS2fw5uRP
5 years 6 months ago
Can you classify SLE by labs only but should you? Serology is part of criteria but why dx with only +ANA, +antiDNA and no other CTD characteristics. Would need cytopenias & RBC casts to think of lab dx of SLE OP0094 @LupusCanada @RheumNow @eular_org #EULAR2020 @CRASCRRheum https://t.co/Jr6SRr3HR1
5 years 6 months ago
Avacopan is as effective as steroids in ANCA Assoc Vasculitis – 330 pt RCT AAV Rx w/ RTX or CTX but randomized to prednisone or avacopan (C5aR antagonist). Avacopan=prednisone remission rates same (72% vs 70%) wk 26 & wk 52 (66% vs 55%). #EULAR2020 #OP0011 https://t.co/WIXJCYkxSb

Dr. John Cush @RheumNow ( View Tweet )

5 years 6 months ago
×